Amgen Inc. $AMGN Shares Sold by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. reduced its Amgen holdings by 4.1%, now owning 444,152 shares valued at approximately $124 million as of its latest SEC filing.
• Amgen reported $6.02 EPS for the last quarter, exceeding analysts' expectations of $5.28, with revenue of $9.18 billion, up 9.4% year-over-year.
• The company recently declared a quarterly dividend of $2.38 per share, yielding 3.2%, with a payout ratio of 77.84%.

Robeco Institutional Asset Management B.V. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 444,152 shares of the medical research company's stock after selling 18,753 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.08% of Amgen worth $124,012,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AMGN. KPP Advisory Services LLC boosted its holdings in shares of Amgen by 87.1% in the 1st quarter. KPP Advisory Services LLC now owns 5,833 shares of the medical research company's stock valued at $1,817,000 after buying an additional 2,716 shares during the period. Advisor Resource Council bought a new position in Amgen in the first quarter worth about $1,331,000. Trinity Legacy Partners LLC boosted its stake in Amgen by 3.9% in the first quarter. Trinity Legacy Partners LLC now owns 16,132 shares of the medical research company's stock valued at $5,026,000 after acquiring an additional 612 shares during the period. DLK Investment Management LLC boosted its stake in Amgen by 7.3% in the first quarter. DLK Investment Management LLC now owns 20,491 shares of the medical research company's stock valued at $6,384,000 after acquiring an additional 1,387 shares during the period. Finally, Founders Financial Alliance LLC grew its holdings in shares of Amgen by 2.7% during the first quarter. Founders Financial Alliance LLC now owns 1,577 shares of the medical research company's stock valued at $491,000 after purchasing an additional 42 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $297.40 on Friday. The stock has a market cap of $160.11 billion, a price-to-earnings ratio of 24.32, a PEG ratio of 2.59 and a beta of 0.49. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $335.88. The stock's 50 day moving average price is $287.51 and its 200 day moving average price is $288.50.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the company posted $4.97 EPS. The firm's quarterly revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen's dividend payout ratio is presently 77.84%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on Amgen from $328.00 to $342.00 and gave the company an "overweight" rating in a research report on Monday, August 25th. Wall Street Zen downgraded shares of Amgen from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. UBS Group lowered their price target on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $305.00 price objective on shares of Amgen in a research report on Tuesday, June 24th. Finally, Citigroup boosted their target price on shares of Amgen from $310.00 to $315.00 and gave the company a "neutral" rating in a research note on Wednesday, September 24th. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Amgen presently has a consensus rating of "Hold" and a consensus price target of $309.70.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company's stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.76% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.